288 related articles for article (PubMed ID: 29688579)
1. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.
Riedl MA; Aygören-Pürsün E; Baker J; Farkas H; Anderson J; Bernstein JA; Bouillet L; Busse P; Manning M; Magerl M; Gompels M; Huissoon AP; Longhurst H; Lumry W; Ritchie B; Shapiro R; Soteres D; Banerji A; Cancian M; Johnston DT; Craig TJ; Launay D; Li HH; Liebhaber M; Nickel T; Offenberger J; Rae W; Schrijvers R; Triggiani M; Wedner HJ; Dobo S; Cornpropst M; Clemons D; Fang L; Collis P; Sheridan WP; Maurer M
Allergy; 2018 Sep; 73(9):1871-1880. PubMed ID: 29688579
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and pharmacodynamics of avoralstat, an oral plasma kallikrein inhibitor: phase 1 study.
Cornpropst M; Collis P; Collier J; Babu YS; Wilson R; Zhang J; Fang L; Zong J; Sheridan WP
Allergy; 2016 Dec; 71(12):1676-1683. PubMed ID: 27154593
[TBL] [Abstract][Full Text] [Related]
3. Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema.
Aygören-Pürsün E; Bygum A; Grivcheva-Panovska V; Magerl M; Graff J; Steiner UC; Fain O; Huissoon A; Kinaciyan T; Farkas H; Lleonart R; Longhurst HJ; Rae W; Triggiani M; Aberer W; Cancian M; Zanichelli A; Smith WB; Baeza ML; Du-Thanh A; Gompels M; Gonzalez-Quevedo T; Greve J; Guilarte M; Katelaris C; Dobo S; Cornpropst M; Clemons D; Fang L; Collis P; Sheridan W; Maurer M; Cicardi M
N Engl J Med; 2018 Jul; 379(4):352-362. PubMed ID: 30044938
[TBL] [Abstract][Full Text] [Related]
4. Interventions for the long-term prevention of hereditary angioedema attacks.
Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat.
Aygören-Pürsün E; Magerl M; Graff J; Martinez-Saguer I; Kreuz W; Longhurst H; Nasr I; Bas M; Straßen U; Fang L; Cornpropst M; Dobo S; Collis P; Sheridan WP; Maurer M
J Allergy Clin Immunol; 2016 Sep; 138(3):934-936.e5. PubMed ID: 27302552
[No Abstract] [Full Text] [Related]
6. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
[TBL] [Abstract][Full Text] [Related]
7. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
Zuraw B; Lumry WR; Johnston DT; Aygören-Pürsün E; Banerji A; Bernstein JA; Christiansen SC; Jacobs JS; Sitz KV; Gower RG; Gagnon R; Wedner HJ; Kinaciyan T; Hakl R; Hanzlíková J; Anderson JT; McNeil DL; Fritz SB; Yang WH; Tachdjian R; Busse PJ; Craig TJ; Li HH; Farkas H; Best JM; Clemons D; Cornpropst M; Dobo SM; Iocca HA; Kargl D; Nagy E; Murray SC; Collis P; Sheridan WP; Maurer M; Riedl MA
J Allergy Clin Immunol; 2021 Jul; 148(1):164-172.e9. PubMed ID: 33098856
[TBL] [Abstract][Full Text] [Related]
8. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
Aygören-Pürsün E; Zanichelli A; Cohn DM; Cancian M; Hakl R; Kinaciyan T; Magerl M; Martinez-Saguer I; Stobiecki M; Farkas H; Kiani-Alikhan S; Grivcheva-Panovska V; Bernstein JA; Li HH; Longhurst HJ; Audhya PK; Smith MD; Yea CM; Maetzel A; Lee DK; Feener EP; Gower R; Lumry WR; Banerji A; Riedl MA; Maurer M
Lancet; 2023 Feb; 401(10375):458-469. PubMed ID: 36774155
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
Craig T; Magerl M; Levy DS; Reshef A; Lumry WR; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygören-Pürsün E; Keith PK; Busse P; Feuersenger H; Pawaskar D; Jacobs I; Pragst I; Doyle MK
Lancet; 2022 Mar; 399(10328):945-955. PubMed ID: 35219377
[TBL] [Abstract][Full Text] [Related]
10. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.
Busse PJ; Farkas H; Banerji A; Lumry WR; Longhurst HJ; Sexton DJ; Riedl MA
BioDrugs; 2019 Feb; 33(1):33-43. PubMed ID: 30539362
[TBL] [Abstract][Full Text] [Related]
11. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
Banerji A; Riedl MA; Bernstein JA; Cicardi M; Longhurst HJ; Zuraw BL; Busse PJ; Anderson J; Magerl M; Martinez-Saguer I; Davis-Lorton M; Zanichelli A; Li HH; Craig T; Jacobs J; Johnston DT; Shapiro R; Yang WH; Lumry WR; Manning ME; Schwartz LB; Shennak M; Soteres D; Zaragoza-Urdaz RH; Gierer S; Smith AM; Tachdjian R; Wedner HJ; Hebert J; Rehman SM; Staubach P; Schranz J; Baptista J; Nothaft W; Maurer M;
JAMA; 2018 Nov; 320(20):2108-2121. PubMed ID: 30480729
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Craig TJ; Reshef A; Li HH; Jacobs JS; Bernstein JA; Farkas H; Yang WH; Stroes ESG; Ohsawa I; Tachdjian R; Manning ME; Lumry WR; Saguer IM; Aygören-Pürsün E; Ritchie B; Sussman GL; Anderson J; Kawahata K; Suzuki Y; Staubach P; Treudler R; Feuersenger H; Glassman F; Jacobs I; Magerl M
Lancet; 2023 Apr; 401(10382):1079-1090. PubMed ID: 36868261
[TBL] [Abstract][Full Text] [Related]
13. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
Ohsawa I; Honda D; Suzuki Y; Fukuda T; Kohga K; Morita E; Moriwaki S; Ishikawa O; Sasaki Y; Tago M; Chittick G; Cornpropst M; Murray SC; Dobo SM; Nagy E; Van Dyke S; Reese L; Best JM; Iocca H; Collis P; Sheridan WP; Hide M
Allergy; 2021 Jun; 76(6):1789-1799. PubMed ID: 33247955
[TBL] [Abstract][Full Text] [Related]
14. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
[TBL] [Abstract][Full Text] [Related]
15. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
[TBL] [Abstract][Full Text] [Related]
16. Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema.
Stolz LE; Horn PT
Drugs Today (Barc); 2010 Aug; 46(8):547-55. PubMed ID: 20830315
[TBL] [Abstract][Full Text] [Related]
17. Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.
Kiani-Alikhan S; Gower R; Craig T; Wedner HJ; Kinaciyan T; Aygören-Pürsün E; Banerji A; Bernstein JA; Anderson J; Collis P; Johnston DT; Desai B; Tomita D; Gagnon R; Tachdjian R; Soteres DF; Farkas H; Caballero T; McNeil D; Jacobs J; Lumry WR;
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):733-743.e10. PubMed ID: 38122865
[TBL] [Abstract][Full Text] [Related]
18. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
[TBL] [Abstract][Full Text] [Related]
19. Nanofiltered human C1 inhibitor concentrate (Cinryze®): in hereditary angioedema.
Lyseng-Williamson KA
BioDrugs; 2011 Oct; 25(5):317-27. PubMed ID: 21942916
[TBL] [Abstract][Full Text] [Related]
20. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency.
Wu MA; Zanichelli A; Mansi M; Cicardi M
Expert Opin Pharmacother; 2016; 17(1):27-40. PubMed ID: 26512744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]